美国学术机构病理医生对新辅助化疗后乳腺癌标本报告实践的调查
该研究基于多学科小组发布的新辅助化疗后标本病理报告标准化建议,向美国学术中心26名乳腺病理医生发送含6个是/否问题的调查。收到19个中心23名病理医生的回复,结果显示学术乳腺病理实践在化疗后肿瘤分级、受体重复检测、瘤床报告、残留癌负荷评分及专用模板使用等方面存在显著差异,并记录了不遵循推荐指南的主要障碍。
要点
- 74%的病理医生在新辅助化疗后仍进行肿瘤分级,26%不进行。
- 65%常规重复激素受体和HER2检测,35%不重复。
- 仅22%有化疗后病例专用报告模板,78%没有。
核心结论
- 学术乳腺病理实践在新辅助化疗后病例的报告上存在显著差异。
- 研究记录了阻碍标准实践的障碍,并提供了促进更统一报告的建议。
研究设计与样本
- 基于多学科小组发布的标准化建议设计问卷,向美国学术中心26名乳腺病理医生发送含6个是/否问题的调查,鼓励附加评论。
- 收到来自19个中心的23名乳腺病理医生的回复。
主要发现
- 化疗后肿瘤分级:17名(74%)是,6名(26%)否。
- 常规重复激素受体和HER2/Neu检测:15名(65%)是,8名(35%)否。
- 切缘有肿瘤消退/瘤床特征但无实际肿瘤时报告:11名(48%)是,8名(35%)否,4名(17%)实践不一。
- 报告纤维化/消退改变淋巴结数量:17名(74%)是,6名(26%)否。
- 报告残留癌负荷评分或提供计算信息:17名(74%)是,6名(26%)否;有专用报告模板:5名(22%)是,18名(78%)否。
关键数值与推荐
- 不遵循推荐指南的主要原因包括病理医生不了解提供信息的预后重要性、报告实践由临床医生驱动以及部分病理医生不知道推荐。
临床怎么用
- 临床应关注新辅助化疗后乳腺癌标本报告的关键要素,包括肿瘤分级、受体状态重复检测、瘤床切缘特征、淋巴结消退改变及残留癌负荷评分。
- 机构可制定专用报告模板以促进标准化报告。
局限性
- 调查仅纳入美国学术中心的乳腺病理医生,样本量有限(23名回复者)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Neoadjuvant chemotherapy is increasingly being used to treat primary invasive breast carcinoma. Response to neoadjuvant chemotherapy is an important determinant of prognosis. A multidisciplinary group published recommendations for standardization of pathologic reporting of postneoadjuvant chemotherapy specimens. Based on these recommendations, we sent a survey to 26 pathologists currently practicing breast pathology in academic centers across the United States. The survey consisted of six questions with yes/no answers. The pathologists were encouraged to add comments. We received responses from 23 breast pathologists from 19 centers. The questions and responses were as follows: 1. Do you grade tumors after neoadjuvant chemotherapy?-17 (74%) responded yes and 6 (26%) responded no. 2. Do you routinely repeat hormone receptors, HER2/Neu results after neoadjuvant chemotherapy?-15 (65%) responded yes and 8 (35%) responded no. 3. If there are features of tumor regression/tumor bed at the margin but no actual tumor at the margin do you report this?-11 (48%) responded yes and 8 (35%) responded no and 4 (17%) reported a variable practice. 4. Do you report number of nodes with fibrosis/changes of regression?-17 (74%) responded yes and 6 (26%) responded no. 5. Do you report residual cancer burden score on your report or at least provide information on your report so clinicians can calculate residual cancer burden?-17 (74%) responded yes and 6 (26%) responded no. 6. Do you have a specific synoptic for cases after neoadjuvant chemotherapy?-5 (22%) responded yes and 18 (78%) responded no. The major reasons provided for nonadherence to recommended guidelines included pathologists were unaware of prognostic importance of providing the information, reporting practices were clinician driven and some pathologists were unaware of the recommendation. We document that academic breast pathology practices show significant variability in reporting of postneoadjuvant chemotherapy cases. We document barriers to standard practice and provide recommendations we hope will contribute to a more uniform reporting practice for these complex specimens.
引用
- Lanjewar S, Patil P, Fineberg S, et al. Pathologic reporting practices for breast cancer specimens after neoadjuvant chemotherapy-a survey of pathologists in academic institutions across the United States. Mod Pathol. 2019. PMID: 31383962. doi:10.1038/s41379-019-0326-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。